Myasthenia gravis is a rare, potentially life-threatening disease that can affect people of any age. The disease is chronic and requires specialist treatment.
Myasthenia gravis is characterised by fluctuating muscle weakness that can even affect respiratory function. When symptoms worsen, patients need immediate and professional help.
​
Lack of access to specialised care can prevent timely treatment decisions and lead to life-threatening crises and intensive care unit stays.
MyaLink closes a gap in patient care. Vital signs are monitored using spirometers and wearables and patients document their symptoms using standardised questionnaires (PROM).
The treating specialist can thus assess the course of the disease remotely and contact the patient and, if necessary, adjust the therapy at an early stage. Therefore, the long periods between appointments with specialists are no longer a black box and crises can be prevented.
FOR PATIENTS
Early detection of disease activity and prevention of crises
MyaLink connects patients and specialists in real time.
Continuous monitoring indicates the need for action at an early stage. Therapy adjustments can be made remotely and in good time. In addition, long-term monitoring provides practitioners with a more complete picture of the patient's clinical condition during routine visits, enabling them to make better treatment decisions. This significantly improves the patient's quality of life.
MyaLink meets the highest standards of data protection.
MONITORING
Recording of vital parameters by spirometer and wearable
DOCUMENTATION
Medication plan with reminder funciton, documentation of laboratory results, digital emergency pass, etc.
COMMUNICATION
Chat function for individual counselling and consultation with specialist
INFORMATION
Updates from science and on events and medical topics
FOR HEALTH CARE PROFESSIONALS
Better treatment outcomes through telemonitoring
Current care is inadequate, poorly organised and frustrating for all involved. As a result, there is little time for far-reaching treatment decisions.
With MyaLink, practitioners have constant access to important parameters to assess the patient's condition and adjust therapy remotely if necessary. This prevents avoidable crises and intensive care unit stays and leads to immense cost savings in the healthcare system.
Our vision is that patients with rare diseases, so-called orphan diseases, receive the best possible care. In Germany alone, 4 million patients suffer from a rare disease.
We believe that every patient - no matter how rare their disease - should have access to a specialist when they need it. Together with monitoring of the course of the disease, this significantly improves the treatment and quality of life for patients with rare diseases.
TEAM
From practice to patient
MyaLink was developed by a team of experts consisting of clinicians and researchers in neurology, together with a technology partner and patients.
Dr. med. Sophie Lehnerer
Medical & Health Economics
Dr. med. Lea Gerischer
Medical & Research
Dr. med. Maike Krause
Medical & Research
Prof. Dr. med. Andreas Meisel
Network & Trials
Qurasoft
Tech Partner
Deutsche Myasthenie Gesellschaft e.V.
Patient organisation
Are you a patient with myasthenia gravis or another rare disease and want to use MyaLink?
Are you a healthcare professional and would like to enable your myasthenia gravis patients to use MyaLink, or do you have further questions?
Would you like to know more about MyaLink and the latest developments?